ERBB2 and breast cancer: Sanz-Moreno et al. (2021) described activating the RANKL signaling pathway raises extracellular signal-regulated kinase (ERK), NF-κB signaling, and lapatinib resistance in several human epidermal growth factor receptor 2 (HER2)-positive BC cells.